# NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC

Source: https://onco.cc/trials/nct07765667/  
OnCo record `nct07765667` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of High-dose intravenous vitamin C in Rectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, not yet recruiting.

## Summary

NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC is a phase 2 interventional study registered as NCT07765667 by Sixth Affiliated Hospital, Sun Yat-sen University, with 100 participants planned, started 2026-09-01 and due to reach its primary completion in 2029-09-01. Interventions recorded: Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen, Ketogenic Diet, Surgical resection, Vitamin C. Conditions recorded: Rectal Adenocarcinoma, High-Risk Cancer, MSS.

Linked to the technology High-dose intravenous vitamin C because the registry's title names it ("high dose intravenous vitamin c") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07765667
- Phase: 2
- Setting: Neoadjuvant Chemoradiotherapy and Immunotherapy Combined With Ketogenic Diet and/or High-Dose Intravenous Vitamin C in pMMR/MSS Locally Advanced Rectal Adenocarcinoma: A Prospective, Multicenter, Phase Ⅱ Clinical Study (CRI-KEV Trial)
- Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07765667: https://clinicaltrials.gov/study/NCT07765667

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [High-dose intravenous vitamin C](https://onco.cc/technologies/high-dose-vitamin-c/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)

---
JSON: https://onco.cc/api/v1/entities/nct07765667.json